Correspondence | Published:

Life sciences venture capital in emerging markets

Nature Biotechnology volume 31, pages 195201 (2013) | Download Citation

  • A Corrigendum to this article was published on 10 June 2013

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 30 April 2013

    In the version of this article initially published, in Table 1, the number of health biotech firms, including those not backed by venture capital, in South Africa, was given as 78 in 2007. It should be 64 in 2010. The error has been corrected in the HTML and PDF versions of the article.

References

  1. 1.

    et al. Nat. Biotechnol. 26, 627–644 (2008).

  2. 2.

    et al. Nat. Biotechnol. 25, 403–417 (2007).

  3. 3.

    et al. Nat. Biotechnol. 26, 37–53 (2008).

  4. 4.

    et al. Nat. Biotechnol. 27, 427–445 (2009).

  5. 5.

    Anonymous. Nat. Rev. Microbiol. 8, 310 (2010).

  6. 6.

    Int. J. 5, 341–357 (2011).

  7. 7.

    et al. Nat. Biotechnol. 27, 229–232 (2009).

  8. 8.

    et al. Nat. Biotechnol. 28, 407–416 (2010).

  9. 9.

    Anonymous. Biotech 2011 Life Sciences: Looking Back to See Ahead (Burrill & Co., 2011).

  10. 10.

    , ed. China Life Science 2012: From Local to Global. (ChinaBio, 2012).

  11. 11.

    East Asian Sci. Technol. Soc. Int. J. 3, 401–420 (2009).

  12. 12.

    Anonymous. Global Life Sciences Cluster Report (Jones Lang LaSalle, 2011).

  13. 13.

    VC investment in China life sciences climbs 300%, tops $1 billion. China Biotech Today (4 February 2011).

  14. 14.

    Anonymous. MoneyTree: Zigzagging Upwards (Pricewaterhouse Coopers, 2012).

  15. 15.

    PhRMA. Private and Public R&D Spending (1995–2009). (1995–2009).

  16. 16.

    Anonymous. Beyond Borders: Global Biotechnology Report (Ernst & Young, 2011).

  17. 17.

    et al. Am. Econ. Rev. 88, 290–306 (1998).

  18. 18.

    Life Sciences R&D: Changing the Innovation Equation in India. US-India BioPharma Summit (Boston Consulting Group, 2011).

  19. 19.

    Boulevard of Broken Dreams: Why Public Efforts to Boost Entrepreneurship and Venture Capital Have Failed–and What to Do About It (Princeton University Press, 2009).

  20. 20.

    & South African Venture Capital Association: 2010 SAVCA Venture Solutions VC Survey (SAVCA, November 2010).

  21. 21.

    & Nat. Rev. Drug Discov. 9, 98 (2010).

  22. 22.

    Anonymous. China Pharmaceuticals. Asian Insight: China has R&D. Morgan Stanley Asia Insight (6 November 2012).

  23. 23.

    et al. Nat. Rev. Drug Discov. 10, 333–334 (2011).

  24. 24.

    Venture Capital: Investment Strategies, Structures and Policies (Wiley & Sons, Hoboken, New Jersey, USA, 2010).

  25. 25.

    Omega 29, 375–390 (2001).

  26. 26.

    Anonymous. GSK devotes unit to traditional Chinese medicine R&D. ChinaBio Today (13 February 2012).

  27. 27.

    Public funding zooms past $650 million for Indian life science. BioSpectrum Asia (14 November 2012).

  28. 28.

    Establishing a biotech industry in Singapore. Genetic Engineering News (15 April 2005).

  29. 29.

    Nature 455, 1143 (2008).

  30. 30.

    Nat. Biotechnol. 29, 1066–1067 (2011).

  31. 31.

    & Harv. Bus. Rev. Blog Network (2011).

  32. 32.

    et al. Nat. Biotechnol. 28, 407–416 (2010).

Download references

Acknowledgements

We gratefully acknowledge B. Pang for assisting with the statistical analysis and translation of the Chinese data.

Author information

Affiliations

  1. Thomas McNerney and Partners, La Jolla, California, USA.

    • Justin Chakma
  2. Wharton School, University of Pennsylvania Health Care Systems, Philadelphia, Pennsylvania, USA.

    • Stephen M Sammut
  3. Rotman School of Management, University of Toronto, Toronto, Ontario, Canada.

    • Ajay Agrawal

Authors

  1. Search for Justin Chakma in:

  2. Search for Stephen M Sammut in:

  3. Search for Ajay Agrawal in:

Competing interests

Justin Chakma is an analyst at a life sciences venture capital firm. Stephen M. Sammut is a venture partner at a life sciences venture capital firm.

Corresponding author

Correspondence to Justin Chakma.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Methods, Supplementary Tables 1 and 2, and Supplementary Figure 1

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2529

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing